Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical technology company focused on cardiovascular device development that became publicly traded through its SPAC merger with Health Assurance Acquisition Corp, sponsored by Health Assurance Acquisition Corp Management, whose IPO priced in 2020. Operating in the medical device and cardiovascular health sector, Orchestra BioMed is advancing lead programs including its BackBeat CNT cardiac pacing system for hypertension and the Virtue SAB sirolimus-eluting scaffold for coronary artery disease. The company filed supplemental definitive proxy soliciting materials (DEFA14A) with the SEC on April 29, 2026, reflecting active shareholder engagement. Sign up at SpacDesk for complete filing histories, sponsor profiles, and real-time data on OBIO and hundreds of other de-SPAC companies.